As we prepare for Q1 2026, sponsors and CROs face a shifting global landscape for clinical trial comparator sourcing that focuses on sustainability, diversity and fair pricing. With our EcoVadis Platinum certification, women-owned business status and full scientific team in place, CSI is well placed to support our partner’s supply chains. 1. Supply-chain volatility is real Clinical supplies are increasingly challenged by geo-political pressures, export controls, and manufactu

Strategy Partnerships for Budget Value As we enter Q4, many clinical operations teams face the familiar challenge of budget utilization. In research-driven organizations, unspent funds create pressure to allocate resources quickly. Yet, reactive decisions can compromise study timelines, inflate costs, or affect compliance. The question becomes: how can sponsors and CROs transform year-end budget pressures into a strategic advantage? From Short-Term Spending to Strategic Inves

Earlier this month, the US President signed a landmark executive order aimed at delivering “most favored nation” (MFN) pricing for...

In clinical trials, every element of the supply chain matters. From sourcing high-quality comparator drugs to managing timelines across borders, sponsors often ask: which is the bigger challenge, drug sourcing or the logistics that follow? At Clinical Services International (CSI), we believe the answer isn’t either/or. It’s how you manage both that determines trial success. Comparator Sourcing: A Global Jigsaw Puzzle Sourcing comparator drugs can be a significant challenge, p

So are we! We’re pleased to share that Jonathan Miller, CSI’s Head of Operations, North America, will be attending Jefferies New York 2025 this June. If you’re a pharmaceutical or biotech company with comparator drugs in your pipeline, from early planning to on-demand global delivery, Jonathan would be happy to connect. Clinical Services International specializes in supporting complex, high-value clinical trials across all therapeutic areas. 📅 Let’s set up a meeting to explo

CSI’s Strategic Approach to Mitigating Clinical Trial Supply Disruption Recent developments in U.S. trade policy are shaking up supply chains, not just within the United States but worldwide. With the re-introduction of Trump-era tariffs on key goods, companies engaged in clinical research must rethink their sourcing and logistics strategies. Clinical Services International (CSI) is proactively addressing these challenges to support our clients amid this uncertain climate. Wh

CSI attended the Global Clinical Supplies Group (GCSG) US Conference in San Antonio, Texas, April 27th-30th. The event brought together clinical supply professionals from around the world to discuss industry trends, challenges and strategies for your clinical trial pipeline. CSI’s Managing Director, Vanessa Dekou, hosted a successful and sell-out workshop at GCSG US, to share over 25 years’ worth of expert insights on the complexities of comparator sourcing strategies. If yo

Exciting news! CSI will be exhibiting at GCSG Asia Pacific 2024 this week, on March 12-13 in Seoul! Visit us at Table 7 to learn how our expert clinical supply solutions can streamline your global trial supplies. Let’s connect and explore how CSI’s direct manufacturer relationships, scientific expertise and sustainable sourcing can support your study needs. See you there! 👋

A Leading Biotech Client's Challenge A leading biotech client approached CSI to assist in sourcing the comparator drug Lucentis for a Phase II ophthalmology clinical trial. This project demanded precise planning and timely execution. It was crucial to ensure an uninterrupted supply across multiple global sites. The client prioritized batch consistency and Certificates of Analysis (CoA) for all supplies. Understanding the Challenges The biotech company faced several hurdles in

We’re excited to announce that Stephan Muetze, Director of Project Management, and Yasmine Clemson, Project Management and Marketing Associate, will be representing CSI at Clinical Trial Supply (CTS) Barcelona on 25th and 26th February. We don’t just support clinical trials—we inspire change, drive progress, and celebrate the power of diversity. Schedule a meeting here: www.csint.com/contact-us

Which Trends Will Shape Clinical Trial Supplies in 2025? The clinical trial supply industry is rapidly evolving. This change is driven by...

CSI is excited to have our Managing Director Vanessa Dekou featured on the front cover of Life Sciences Magazine! This recognition is not only a personal achievement but a testament to the incredible work of the Clinical Services International team. We have been driving excellence in clinical trial services, making a real impact to clinical research and patients lives. Read the Life Sciences Review article here.

Ensuring Efficiency, Compliance and Success Full supply chain management in clinical trial supply encompasses the comprehensive oversight and coordination of all activities involved in the sourcing, packaging, distribution and management of clinical trial comparator drugs and ancillaries. The goal is to ensure that these materials are available at the right place, at the right time, in the right condition, and in the correct quantities, all while complying with regulatory req

CSI's Director of Strategy, Andrea Giochetta is attending BioNJ's BioPartnering Conference at the Liberty Science Centre in New Jersey on...

Ancillaries play a crucial role in ensuring the smooth execution of clinical trials, encompassing a broad range of items, materials and services beyond the investigational product itself. From medical and wearable devices and diagnostic tools to specialized equipment, ancillaries are indispensable components of the clinical trial supply chain. What are Ancillaries? Ancillaries refer to any supplementary items or services required for the proper functioning of a clinical tri

Ryvu Therapeutics Announces Entering into Agreement with Clinical Services International (CSI) in the Area of Securing Venetoclax Supply...

The growth in the biosimilar market since 2006 has been significant. Biosimilars have no meaningful clinical differences between the...